CCCC — C4 Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662579 ·
Last close
$2.53
Market Cap
$332.23M
52W High
$5.17
52W Low
$1.69
ADV30
2,960,042
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 8,468,000 | — | -24,596,000 | -21,843,000 | 331,800,000 | 32,425,000 | 103,632,000 |
| Jun 2026 | 6,641,000 | — | -26,423,000 | -23,635,000 | 359,404,000 | 78,610,000 | 112,139,000 |
| Mar 2026 | 6,152,000 | — | -27,785,000 | -25,129,000 | 328,861,000 | 61,274,000 | 94,614,000 |
| Dec 2025 | 11,016,000 | — | -23,145,000 | -20,486,000 | 359,075,000 | 74,603,000 | 102,488,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-79,629,000
Investing CF
$-99,973,000
Financing CF
$153,218,000
CapEx
$-523,000
Dividends Paid
—
Buybacks
$-253,000
EPS Diluted TTM
$-0.72
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-809,300,000
Inventory
—
Receivables
$1,405,000
ST Investments
$172,973,000
EBIT TTM
$-101,949,000
Pretax Income TTM
$-90,972,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,039,000
EBITDA
$-99,448,000
Free Cash Flow
$-43,664,000
Enterprise Value
$187,033,424
Total Cash
$253,663,008
Total Debt
$56,858,000
Shares Out
131,317,488
Trailing EPS
$-0.63
Book Value
$2.65
ROE
-48.1%
ROA
-19.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,947,000 | -104,489,000 | -104,994,000 | 359,075,000 | 102,488,000 | 256,587,000 | -98,694,000 |
| Dec 2024 | 35,584,000 | -117,177,000 | -105,316,000 | 349,602,000 | 133,616,000 | 215,986,000 | -65,157,000 |
| Dec 2023 | 20,756,000 | -139,031,000 | -132,493,000 | 376,451,000 | 130,337,000 | 246,114,000 | -106,838,000 |
| Dec 2022 | 31,096,000 | -129,534,000 | -128,175,000 | 430,840,000 | 141,606,000 | 289,234,000 | -105,939,000 |
TTM Snapshot
Revenues TTM
$35,039,000
NetIncome TTM
$-101,416,000
OpCashFlow TTM
—
Assets (Latest)
$359,404,000
Forward EPS
$-0.92
Max Pain — expiry 2027-04-16
max pain strike: $4.00 · spot: $2.47 · call oi: 5,010 · put oi: 382
Expected Move to 2027-04-16:
±$1.25
(50.51%) —
implied range
$1.22 –
$3.72
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JSPR | Jasper Therapeutics, Inc. | $344.06M | $10.34 | — |
| XFOR | X4 Pharmaceuticals, Inc | $315.53M | $3.09 | — |
| SLBT | SL Science Holding Ltd | $356.14M | $0.64 | — |
| SCTX | Scribe Therapeutics, Inc. | $298.64M | $15.77 | — |
| KYTX | Kyverna Therapeutics, Inc. | $297.14M | $4.70 | — |
News headlines (Yahoo Finance, 1h cache)
Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?
2026-11-18 13:40 · Yahoo
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 13:35 · Yahoo
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 12:00 · Yahoo
C4 Therapeutics to Participate in Upcoming November Investor Conferences
2026-11-03 12:00 · Yahoo
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 21:01 · Yahoo
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
2026-10-29 11:00 · Yahoo
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-09-23 13:40 · Yahoo
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd I
2026-09-03 11:00 · Yahoo
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.